Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Humacyte (HUMA)
NASDAQ:HUMA
Humacyte (HUMA) Stock Price & Analysis
361 Followers
HUMA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.96 - $5.60
Previous Close$3.59
Volume5.79M
Average Volume (3M)1.19M
Market Cap
$427.51M
Enterprise Value$404.57M
Total Cash (Recent Filing)$80.45M
Total Debt (Recent Filing)$57.51M
Price to Earnings (P/E)-3.4
Beta1.80
Next Earnings
May 10, 2024EPS Estimate
-$0.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.07
Shares Outstanding119,083,728
10 Day Avg. Volume1,135,302
30 Day Avg. Volume1,188,175
Standard Deviation0.20
R-Squared0.14
Alpha-0.04
Financial Highlights & Ratios
Price to Book (P/B)26.90
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.80
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-5.42
Forecast
1Y Price Target
$8.00Price Target Upside122.84% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
Humacyte News
Bulls Say, Bears Say
Bulls Say
Market OpportunityThe market for vascular trauma treatment is substantial, and with HUMA's Human Acellular Vessel targeting a significant part of this market, the financial upside could be considerable.
Regulatory MilestoneThe FDA's acceptance of HUMA's Biologics License Application for the Human Acellular Vessel signifies a key regulatory milestone, potentially expediting its availability for vascular trauma care.
Strategic PartnershipsFresenius, being the largest shareholder and committed to adopting the Human Acellular Vessel as standard care, underscores the confidence in the product's potential and market acceptance.
Bears Say
Financial PerformanceTreatment of AV access complications in certain patient groups can lead to substantial Medicare costs.
Healthcare CostsFemales and African American patients with End-Stage Renal Disease face high rates of complications with arteriovenous (AV) access treatments.
Healthcare EconomicsObese and diabetic women, as high-risk subgroups, may incur even higher treatment costs for AV access complications.
---
Ownership Overview
20.74% Insiders
3.99% Mutual Funds
7.94% Other Institutional Investors
67.33% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
HUMA FAQ
What was Humacyte’s price range in the past 12 months?
Humacyte lowest stock price was $1.96 and its highest was $5.60 in the past 12 months.
What is Humacyte’s market cap?
Currently, no data Available
When is Humacyte’s upcoming earnings report date?
Humacyte’s upcoming earnings report date is May 10, 2024 which is in 20 days.
How were Humacyte’s earnings last quarter?
Humacyte released its earnings results on Mar 22, 2024. The company reported -$0.24 earnings per share for the quarter, the consensus estimate of -$0.24 by $0.
Is Humacyte overvalued?
According to Wall Street analysts Humacyte’s price is currently Undervalued.
Does Humacyte pay dividends?
Humacyte does not currently pay dividends.
What is Humacyte’s EPS estimate?
Humacyte’s EPS estimate is -$0.23.
How many shares outstanding does Humacyte have?
Humacyte has 119,083,725 shares outstanding.
What happened to Humacyte’s price movement after its last earnings report?
Humacyte reported an EPS of -$0.24 in its last earnings report, expectations of -$0.24. Following the earnings report the stock price went down -8.056%.
Which hedge fund is a major shareholder of Humacyte?
Among the largest hedge funds holding Humacyte’s share is Clough Capital Partners L P. It holds Humacyte’s shares valued at 367K.
---
Humacyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$8.00 (122.84% Upside)
$8.00 (122.84% Upside)
Blogger Sentiment
Bullish
HUMA Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 82.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▲ 0.6%
Last 30 Days ▼ 2.4%
Last 30 Days ▼ 2.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-8.50%
12-Months-Change
Fundamentals
Return on Equity
-169.81%
Trailing 12-Months
Asset Growth
-37.24%
Trailing 12-Months
Company Description
Humacyte
Alpha Healthcare Acquisition Corp is a blank check company.
---
HUMA Earnings Call
Q4 2024
0:00 / 0:00
---
HUMA Stock 12 Months Forecast
Average Price Target
$8.00
▲(122.84% Upside)
Technical Analysis
Best Analysts Covering HUMA
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-8.40%
reiterated a buy rating 23 days ago
Copying Josh Jennings's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -8.40% per trade.
---